MERCK CO. DL-,01/ US58933Y1055 /
2024-05-29 6:54:27 PM | Chg. +0.200 | Volume | Bid6:59:04 PM | Ask6:59:04 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
116.200EUR | +0.17% | 3,406 Turnover: 394,088.800 |
116.200Bid Size: 430 | 116.400Ask Size: 430 | 293.74 bill.EUR | - | - |
GlobeNewswire
1:02 PM
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
8:00 AM
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-06
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
03-06
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-19
Unnatural Products, Inc. Announces $32 Million in Series A Funding Led by Merck Global Health Innova...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-12-12
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degr...
GlobeNewswire
2023-12-05
HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR...
GlobeNewswire
2023-12-04
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
GlobeNewswire
2023-11-13
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA